(NASDAQ: MCRB) Seres Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.07%.
Seres Therapeutics's earnings in 2025 is $85,966,000.On average, 2 Wall Street analysts forecast MCRB's earnings for 2025 to be -$8,667,024, with the lowest MCRB earnings forecast at -$10,067,756, and the highest MCRB earnings forecast at -$7,266,293. On average, 2 Wall Street analysts forecast MCRB's earnings for 2026 to be -$93,279,943, with the lowest MCRB earnings forecast at -$101,202,829, and the highest MCRB earnings forecast at -$85,357,058.
In 2027, MCRB is forecast to generate -$15,408,043 in earnings, with the lowest earnings forecast at -$15,408,043 and the highest earnings forecast at -$15,408,043.